MHC Class II subsets in B Lymphocyte Biology
B 淋巴细胞生物学中的 MHC II 类亚群
基本信息
- 批准号:7708324
- 负责人:
- 金额:$ 23.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-05 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:Antigen Presentation PathwayAntigen-Presenting CellsB-LymphocytesBindingBiochemicalCD4 Positive T LymphocytesCalcium SignalingCarbohydratesCell CommunicationCell DeathCell FractionationCell Surface ProteinsCell membraneCell surfaceCellsComplexDataEpitopesExhibitsFundingGoalsHaplotypesHistocompatibility Antigens Class IIHumoral ImmunitiesImmunizationIntegral Membrane ProteinKnowledgeLabelLinkLiquid substanceLymphocyte BiologyLymphomaMajor Histocompatibility ComplexMediatingMembraneMembrane LipidsMembrane MicrodomainsMolecularMolecular StructureMonoclonal AntibodiesPathway interactionsPatientsPeptidesPhasePhysiologic pulsePositioning AttributePost-Translational Protein ProcessingPropertyProtein FamilyProteinsPublishingReceptor SignalingReceptors, Antigen, B-CellRelative (related person)Research PersonnelResearch Project GrantsRestRoleSignal TransductionSurfaceT-LymphocyteTestingUp-RegulationVaccinationantigen processingbasecancer cellcombinatorialdimerimprovedinsightmemberpalmitoylationpublic health relevancesrc-Family Kinasestumor
项目摘要
DESCRIPTION (provided by applicant): In addition to mediating activation of CD4 T cells, antigenic peptide-MHC class II complexes transduce signals leading to antigen presenting cell activation. Using well-characterized anti-I-Ak monoclonal antibodies (mAbs) that have been available for over 20 years, we recently established that these mAbs differ in their ability to elicit class II signaling in resting B cells. Specifically, a mAb that binds the 1 chain Ia.2 epitope elicits src family kinase-mediated calcium signaling, while two mAbs that bind the 2 chain Ia.17 epitope do not. In preliminary data presented in this proposal, we further demonstrate that the Ia.2 epitope is not present on all I-Ak molecules as previously thought, but rather marks a subset of cell surface I-Ak class II molecules. Further, in addition to its unique signaling capacity the Ia.2+ subset of I-Ak molecules is highly enriched in lipid rafts, critically involved in initiation of cognate MHC-restricted B cell-T cell interactions, and uniquely associated with a low MW cell surface protein. Based on these published and preliminary results, we put forth the hypothesis that the Ia.2 epitope represents a unique molecular structure generated, or rendered accessible, on a subset of signaling-competent lipid raft-tropic I-Ak class II molecules, which are critically important to key MHC class II functions such as B cell signaling and formation of cognate B cell-T cell interactions. To test this hypothesis, we will accomplish two Specific Aims. First, we will further establish the molecular structure of the Ia.2-bearing lipid raft-tropic signaling-competent subset of I-Ak class II molecules. Second, we will establish the sub-cellular compartment in which Ia.2- bearing I-Ak class II molecules are formed. Completion of these specific aims will reveal the basic molecular mechanism behind the unique signaling properties of Ia.2+ I-Ak class II molecules, establish a molecular mechanism controlling the selective lipid raft partitioning of Ia.2+ I-Ak class II molecules (and other MHC class II haplotypes), and lay the groundwork for the further characterization the role Ia.2+ and other MHC class II subsets in BCR-mediated antigen processing / presentation. PUBLIC HEALTH RELEVANCE: B cell and other antigen presenting cells (APCs) express cell surface proteins called major histocompatibility complex (MHC) class II molecules. Cellular activation signals delivered to these cells through MHC class II molecules are important physiologically for antibody-based immunity (e.g. successful vaccination). Therapeutically, anti-MHC II monoclonal antibodies have been used in lymphoma patients to help eliminate malignant cells by triggering cell death. The increased knowledge of B cell MHC class II signaling gained during this research project will support a greater ability to harness MHC class II signaling for improved immunization and anti-tumor therapy.
描述(由申请人提供):除了介导CD4 T细胞的活化外,抗原肽- mhc II类复合物转导导致抗原提呈细胞活化的信号。使用已经存在超过20年的特性良好的抗i- ak单克隆抗体(mab),我们最近发现这些单克隆抗体在静止B细胞中诱导II类信号传导的能力不同。具体来说,结合1链Ia.2表位的单克隆抗体会引发src家族激酶介导的钙信号,而结合2链Ia.17表位的两种单克隆抗体则不会。在本提案提供的初步数据中,我们进一步证明了Ia.2表位并不像之前认为的那样存在于所有I-Ak分子上,而是标记了细胞表面I-Ak II类分子的一个子集。此外,除了其独特的信号传导能力外,I-Ak分子的Ia.2+亚群在脂筏中高度富集,关键参与同源mhc限制性B细胞- t细胞相互作用的启动,并且独特地与低MW细胞表面蛋白相关。基于这些已发表的初步结果,我们提出了这样的假设,即Ia.2表位代表了一种独特的分子结构,这种分子结构是在一组具有信号能力的脂质筏性I-Ak II类分子上产生的,或者可以接近的,这些分子对关键的MHC II类功能(如B细胞信号传导和同源B细胞-t细胞相互作用的形成)至关重要。为了验证这一假设,我们将实现两个具体目标。首先,我们将进一步建立I-Ak II类分子中携带ia .2的脂质筏性信号传导亚群的分子结构。其次,我们将建立亚细胞区室,在其中形成含i .2的I-Ak类分子。这些特定目标的完成将揭示Ia.2+ I-Ak II类分子独特信号特性背后的基本分子机制,建立控制Ia.2+ I-Ak II类分子(以及其他MHC II类单倍型)选择性脂质分流的分子机制,并为进一步表征Ia.2+和其他MHC II类亚群在bcr介导的抗原加工/递呈中的作用奠定基础。公共卫生相关性:B细胞和其他抗原提呈细胞(APCs)表达称为主要组织相容性复合体(MHC) II类分子的细胞表面蛋白。通过MHC II类分子传递给这些细胞的细胞激活信号对基于抗体的免疫(例如成功接种疫苗)具有重要的生理意义。在治疗上,抗mhc II单克隆抗体已用于淋巴瘤患者,通过触发细胞死亡来帮助消除恶性细胞。在本研究项目中获得的对B细胞MHC II类信号的更多了解将支持更好地利用MHC II类信号来改进免疫和抗肿瘤治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James R Drake其他文献
James R Drake的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James R Drake', 18)}}的其他基金
Development of Conformer-Specific Anti-HLA Class II mAbs
构建体特异性抗 HLA II 类单克隆抗体的开发
- 批准号:
10330612 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
Coincident Antigen Processing Pathways Feed M1 and M2 MHC Class II Conformers
一致抗原加工途径喂养 M1 和 M2 MHC II 类适形者
- 批准号:
10303345 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
Characterization of the MHC Class II Peptide Loading Complex
MHC II 类肽装载复合物的表征
- 批准号:
8517574 - 财政年份:2012
- 资助金额:
$ 23.61万 - 项目类别:
Characterization of the MHC Class II Peptide Loading Complex
MHC II 类肽装载复合物的表征
- 批准号:
8383558 - 财政年份:2012
- 资助金额:
$ 23.61万 - 项目类别:
MHC Class II subsets in B Lymphocyte Biology
B 淋巴细胞生物学中的 MHC II 类亚群
- 批准号:
7860479 - 财政年份:2009
- 资助金额:
$ 23.61万 - 项目类别:
Establishing the Molecular Mechanisms of BCR Endocytosis
建立 BCR 内吞作用的分子机制
- 批准号:
7624711 - 财政年份:2007
- 资助金额:
$ 23.61万 - 项目类别:
Establishing the Molecular Mechanisms of BCR Endocytosis
建立 BCR 内吞作用的分子机制
- 批准号:
7315396 - 财政年份:2007
- 资助金额:
$ 23.61万 - 项目类别:
Establishing the Molecular Mechanisms of BCR Endocytosis
建立 BCR 内吞作用的分子机制
- 批准号:
7431758 - 财政年份:2007
- 资助金额:
$ 23.61万 - 项目类别:
Establishing the Molecular Mechanisms of BCR Endocytosis
建立 BCR 内吞作用的分子机制
- 批准号:
7869374 - 财政年份:2007
- 资助金额:
$ 23.61万 - 项目类别:
Establishing the Molecular Mechanisms of BCR Endocytosis
建立 BCR 内吞作用的分子机制
- 批准号:
8072067 - 财政年份:2007
- 资助金额:
$ 23.61万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 23.61万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 23.61万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 23.61万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 23.61万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 23.61万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 23.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




